MONMOUTH JUNCTION, N.J., Oct. 21, 2005 (PRIMEZONE) -- VioQuest Pharmaceuticals, Inc. (OTCBB:VQPH) has accepted an invitation to present at the 3rd Annual PIPEs Conference 2005 on October 26 and 27 at the Waldorf-Astoria Hotel in New York City. Daniel Greenleaf, VioQuest's President and CEO, will be making presentations at 11:00 AM and 2:00 PM EDT on Wednesday, October 26 and at 10:00 AM EDT on Thursday, October 27.
Mr. Greenleaf will provide a company overview along with an update on current operations and new developments, using both an audio and visual arrangement. A webcast will be available on VioQuest's website for 90 days following the conference, at www.vioquestpharm.com.
Conference officials estimate this year's audience to be in excess of 1,000 people, consisting primarily of investors, investment bankers, attorneys, company executives and industry analysts active in the small cap equity market. The conference includes CLE-accredited workshops, roundtables, and presentations from leading industry professionals. Information about the event can be found at www.thepipesconference.com.
About VioQuest Pharmaceuticals, Inc.
VioQuest Pharmaceuticals, Inc.'s strategy is to acquire, develop, and commercialize targeted late preclinical and early clinical stage therapies with unique mechanisms of action for oncology, viral and autoimmune disorders. The Company is developing two novel anti-cancer agents VQD-001 and VQD-002 for the treatment of melanoma, myeloma, lymphoma; and breast, ovarian, pancreatic, colorectal cancers, respectively. VioQuest's life science subsidiary, Chiral Quest, Inc., a pioneer in asymmetric synthesis, offers proprietary chiral catalysts and synthesis expertise for creating important chiral intermediates and products, which improves the safety, efficacy and manufacturing efficiency of pharmaceutical products. Through Chiral Quest, VioQuest provides products and services to fine chemical manufacturers and twelve of the top eighteen pharmaceutical companies worldwide. For more information please visit www.vioquestpharm.com.
Forward-Looking Statements: This press release contains forward-looking statements that involve risks and uncertainties that could cause VioQuest's actual results and experiences to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties, which could cause actual outcomes and results to differ materially from these statements. Among other things, there can be no assurances that any of VioQuest's research programs and compounds will be successfully commercialized, or that the proposed acquisition of Greenwich Therapeutics will be completed. Risks, uncertainties and assumptions also include the possibility that the market for the sale of certain products may not develop as expected; and that development of these products may not proceed as planned. Additional risks are described in VioQuest's Annual Report on Form 10-KSB for the year ended December 31, 2004. VioQuest assumes no obligation and does not intend to update these forward-looking statements, except as required by law.